Journal: Pathology and Oncology Research

Article Title: Pathological Changes and Expression of JAK-STAT Signaling Pathway Hallmark Proteins in Rat Retinas at Different Time Points After Retinal Ischemia Reperfusion Injury

doi: 10.3389/pore.2022.1610385

Figure Lengend Snippet: Immunohistochemistry staining showing protein expression and localization of JAK2, STAT3, p-JAK2, p-STAT3, Bcl-2, and Bax in control, RIRI 0, 6, 24, 72, and 144 h groups. (A) Protein expression of JAK2, STAT3, p-JAK2, p-STAT3, Bcl-2, and Bax in six groups. Scale bar = 50 μm. (B–G) Analysis of JAK2 (B) , STAT3 (C) , p-JAK2 (D) , p-STAT3 (E) , Bcl-2 (F) , and Bax (G) in six groups. N = 5 sections for measuring per group. Compared with control group; ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Primary antibodies were as follows: JAK2 (bs-23003r, Bioss), STAT3 (60199-1-lg, Proteintech), p-JAK2 (ab32101, Abcam), p-STAT3 (sc-8059, Santa), Bcl-2 (ab194583, Abcam), and Bax (A19684, ABclonal).

Techniques: Immunohistochemistry, Staining, Expressing

Journal: Pathology and Oncology Research

Article Title: Pathological Changes and Expression of JAK-STAT Signaling Pathway Hallmark Proteins in Rat Retinas at Different Time Points After Retinal Ischemia Reperfusion Injury

doi: 10.3389/pore.2022.1610385

Figure Lengend Snippet: The hallmarker protein expression of JAK-STAT signaling pathway in control, RIRI 0, 6, 24, 72, and 144 h groups. (A) Protein expression of JAK2, p-JAK2, STAT3, and p-STAT3 in six time points groups. (B–E) Analysis of JAK2 (B) , p-JAK2 (C) , STAT3 (D) , and p-STAT3 (E) in six groups. N = 3–6 repeats per group. Compared with control group, ns, no significance, * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Primary antibodies were as follows: JAK2 (bs-23003r, Bioss), STAT3 (60199-1-lg, Proteintech), p-JAK2 (ab32101, Abcam), p-STAT3 (sc-8059, Santa), Bcl-2 (ab194583, Abcam), and Bax (A19684, ABclonal).

Techniques: Expressing

Journal: medRxiv

Article Title: Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19

doi: 10.1101/2022.03.10.22272123

Figure Lengend Snippet: (A ) STAT1 expression in the lung after 4-day culture in the presence of IFN beta with or without hydrocortisone (HC). ( B) pSTAT1 expression in the same specimens as in A. ( C) Example photomicrographs showing higher STAT2 expression in a TT patient than in a CT patient and the effect of HC on its nuclear translocation. Most STAT2 remains in the cytoplasm of the CT patients, whereas nuclear expression is prominent in the TT patient. Indicated insets are shown in the bottom row. Arrows. ( D ) Combined results of all patients noting that two CT samples are excluded in the data as the patients were already under glucocorticoid treatment at the time of sample acquisition. Ns, not significant; *P<0.05; **P<0.01; and ***P<0.001

Article Snippet: The first stage antibodies were anti-alpha chain of the IFN alpha/beta receptor (St John’s Laboratory STJ112765) that was used 1:2000 and 1:5000 and anti-Stat1 (1:400, 9175S), anti-pStat1(1:100, 9167S) and anti-Stat2 (1:200, 72604S) all from Cell Signalling.

Techniques: Expressing, Translocation Assay

Journal: Oncogene

Article Title: An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia.

doi: 10.1038/sj.onc.1205767

Figure Lengend Snippet: Figure 5 Tyrosine phosphorylation of (a) anti-JAK2 and (b) anti-G-CSFR immunoprecipitates from Ba/F3 transfectants sti- mulated with or without 100 ng/ml G-CSF for 3 min or 10 ng/ ml mIL-3 for 10 min. Lysates were immunoprecipitated with anti-JAK2 or anti-G-CSFR antibodies; blots were probed with the phospho-tyrosine specific antibody PY99, stripped and re- probed with antibody against JAK2 or G-CSFR

Article Snippet: Western blots were probed with PY99, a phosphotyrosine specific antibody (Santa Cruz Biotechnology), then stripped and re-probed with antibody against JAK2 or the receptor.

Techniques: Phospho-proteomics, Immunoprecipitation

Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 3 SNORD52 mediates M2 macrophage polariza- tion and activates JAK2/ STAT6 pathway. A Following transfection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the mRNA expression of SNORD52 was detected by qRT-PCR. ****P < 0.0001 vs. OE-NC. B Following trans- fection of OE-SNORD52/ OE-NC in THP-1 and U937 for 48 h, the protein levels of Arginase-1 and CD163 were determined through Western blotting. *P < 0.05, **P < 0.01, ***P < 0.001 vs. OE-NC. C The ratio of CD206-positive or CD163-positive cells following transfection of OE-SNORD52/ OE-NC was analyzed by flow cytometry. ***P < 0.001 vs. OE-NC. D Following transfec- tion of OE-SNORD52/OE-NC in THP-1 and U937 for 48 h, the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. OE-NC. E The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the mRNA expression of SNORD52 was detected by qRT-PCR. *P < 0.05, **P < 0.01, ***P < 0.001 vs. ASO-NC. F The IL-4 and IL-13 treated THP-1/U937 mac- rophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the protein levels of Arginase-1 and CD163 were determined through Western blotting. ***P < 0.001 vs. ASO-NC. G The ratio of CD206-positive or CD163-positive cells following transfection of SNORD52- ASO-1/-2 or ASO-NC was analyzed by flow cytometry. ***P < 0.001 vs. ASO-NC. (H) The IL-4 and IL-13 treated THP-1/ U937 macrophages were co-incubated with SNORD52 ASO-1/-2 or ASO-NC for 48 h, and then the levels of JAK2/STAT6 pathway-related proteins were determined through Western blotting. ***P < 0.001 vs. ASO-NC. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Transfection, Expressing, Quantitative RT-PCR, Western Blot, Flow Cytometry, Incubation

Journal: Discover oncology

Article Title: Hepatoma cell-derived exosomal SNORD52 mediates M2 macrophage polarization by activating the JAK2/STAT6 pathway.

doi: 10.1007/s12672-024-01700-y

Figure Lengend Snippet: Fig. 5 Huh7 cells-derived exosomal SNORD52 mediates M2 macrophage polarization through activating JAK2/STAT6 pathway. A Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the levels of JAK2/STAT6 pathway-related pro- teins in receptor THP-1 macrophages were measured by Western blotting. B Following the establishment of co-culture model, AG-490 (a specific JAK2 inhibitor) was added and the ratio of CD206-positive or CD163-positive THP-1 macrophages was analyzed by flow cytometry. **P < 0.01, ***P < 0.001. ns: no significance

Article Snippet: Meanwhile, the primary antibodies Arginase-1, CD163, and STAT6 used in Western blotting were also purchased from Proteintech, while other primary antibodies including JAK2, p-JAK2, p-STAT6, exosome-positive markers (CD81 and TSG101), and the corresponding HRP-conjugated secondary antibodies were available from Abcam (Cambridge, UK).

Techniques: Derivative Assay, Co-Culture Assay, Western Blot, Flow Cytometry

Journal: Cells

Article Title: The Regulatory Effects of JAK2/STAT3 on Spermatogenesis and the Redox Keap1/Nrf2 Axis in an Animal Model of Testicular Ischemia Reperfusion Injury

doi: 10.3390/cells12182292

Figure Lengend Snippet: The effect of AG490 on the phosphorylation of JAK2 and STAT3. ( A ) Representative pictures of Western blots demonstrating the protein levels of the phosphorylated forms of JAK2 and STAT3. ( B ) Diagrammatic blot demonstrating the signal intensity quantification of the phosphorylation ratios of p-JAK2/JAK2 and p-STAT3/STAT3. The values are presented as the mean ± SD ( n = 6/group), p -value < 0.05. * tIRI compared to sham and # AG490-treated compared to tIRI. Abbreviations: JAK = Janus kinase; STAT = signal transducer and activator of transcription; tIRI = testicular ischemia reperfusion injury; I = Ipsilateral.

Article Snippet: The primary antibodies for JAK2 (ab108596) and ph-JAK2 (ab195055) were purchased from abcam (Cambridge, UK).

Techniques: Western Blot

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signaling pathway in LPS-induced BV2. (A) Quantification of the p-JAK2/JAK2 in LPS-induced BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in LPS-induced BV2 (n = 3). (C) Quantification of the HMGB1 in LPS-induced BV2 (n = 3). (D) Quantification of the HMGB1 in the cytoplasm in LPS-induced BV2 (n = 3). (E) Quantification of the HMGB1 in the nucleus in LPS-induced BV2 (n = 3). Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-10 μg/mL group, △ p < 0.05, △△ p < 0.01, △△△ p < 0.001.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: Effect of BG on JAK2/STAT3/HMGB1 signalling pathway in brain tissue of MCAO rats. (A–C) Expression of HMGB1 in brain, lung tissues and serum (n = 6). (D) Quantification of the p-JAK2/JAK2 in brains (n = 3). (E) Quantification of the p-STAT3/STAT3 in brains (n = 3). (F) Quantification of the HMGB1 in brains (n = 3). (G) Quantification of the HMGB1 in the cytoplasm in brains (n = 3). (H) Quantification of the HMGB1 in the nucleus in brains (n = 3). (I) Immunofluorescence assay of HMGB1 in brain tissues. Compared with the sham group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05, ## p < 0.01, ### p < 0.001; compared with the BG-25 mg/kg group, △ p < 0.05, △△ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Expressing, Immunofluorescence

Journal: Frontiers in Pharmacology

Article Title: Baicalin-geniposide attenuates pulmonary inflammation and vascular injury via HMGB1 blockade: insights from a cerebral ischemia-reperfusion model and implications for pulmonary hypertension

doi: 10.3389/fphar.2026.1822890

Figure Lengend Snippet: In LPS-induced BV2, BG reduces JAK2 activation and blocks the JAK2-STAT3-HMGB1 pathway, thereby reducing the inflammatory response. (A) Quantification of the p-JAK2/JAK2 in BV2 (n = 3). (B) Quantification of the p-STAT3/STAT3 in BV2 (n = 3). (C) Quantification of the HMGB1 in BV2 (n = 3). (D) Immunofluorescence assay of HMGB1. Compared with the control group, ** p < 0.01, *** p < 0.001; compared with the model group, # p < 0.05; compared with the BG-50 μg/mL group, △ p < 0.05, △△ p < 0.01; compared with the CA1 group, ○ p < 0.05, ○○ p < 0.01.

Article Snippet: Primary antibodies added: anti-JAK2 antibody (CellSignalingTechnology, 1:1,000), anti-STAT3 (Servicebio, 1:500), anti-P-JAK2 (CellSignalingTechnology, 1:1,000), anti-P-STAT3(Servicebio, 1:500), anti-HMGB1 (Servicebio, 1:1,000),anti-β-actin (Servicebio, 1:500),anti-β-tubulin (Proteintech, 1:10,000),anti-LaminB1 (immunoway, 1:1,000).

Techniques: Activation Assay, Immunofluorescence, Control

Journal: bioRxiv

Article Title: Leptin Resistance in the Ovary of Obese Mice Is Associated with Profound Changes in the Transcriptome of Cumulus Cells

doi: 10.1101/729657

Figure Lengend Snippet: Abundance of mRNA (grey box) and protein of leptin signalling pathway components in ovarian extracts collected from animals injected with saline (C) or 100 μg of leptin (L) for 9 or 16 days (d) and sacrificed in oestrus stage. Expression of (A) leptin receptor (ObR), phosphorylation of (B) tyrosine 985 of leptin receptor, (C) tyrosine 1077 of leptin receptor, (D) tyrosine 1138 of leptin receptor, (E) Janus kinase 2 (JAK2), (F) signal transducer and activator of transcription 3 (STAT3), (G) STAT5, expression of (H) protein tyrosine phosphatase 1B (PTP1B) and (I) suppressor of cytokine signaling 3 (SOCS3) determined by real-time PCR and Western blot. (J) SOCS3 ovarian quantification in animals in oestrus stage determined by ELISA. mRNA expression of Rpl37 and protein expression of β-actin was used to normalize the expression data. Each bar represents the mean ± SD. Differences between groups were analysed by Mann-Whitney test. N=4-8 for immunoblots and N=8 for RT PCR analysis and ELISA. * p<0.05; ** p<0.01; ***p<0.001; + p=0.09.

Article Snippet: The expression of other leptin signalling pathway components was assessed using the following antibodies: RP against JAK2 (1:200, cat# sc-294, Santa Cruz Biotechnology), RP against phosphorylated Tyr 1007/1008 JAK2 (pJAK2; 1:200, cat# sc-16566-R, Santa Cruz Biotechnology), RP against STAT3 (1:200, cat# sc-482, Santa Cruz Biotechnology), MM against phosphorylated Tyr 705 pSTAT3 (1:200, cat# sc-8059, Santa Cruz Biotechnology), RP against STAT5 (1:200, cat# sc-835, Santa Cruz Biotechnology), MM against phosphorylated Tyr 694/699 pSTAT5 (1:200, cat# sc-81524, Santa Cruz Biotechnology), GP against PTP1B (1:200, cat# sc-1718, Santa Cruz Biotechnology), MM against SOCS3 (1:500, cat# sc-51699, Santa Cruz Biotechnology) in cell lysates.

Techniques: Injection, Saline, Expressing, Phospho-proteomics, Real-time Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Reverse Transcription Polymerase Chain Reaction